- Home
- INVE vs IMUX Comparison
INVE vs IMUX Comparison
Compare INVE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | IMUX |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 75.2M |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | INVE | IMUX |
|---|---|---|
| Price | $3.58 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $5.50 | $4.80 |
| AVG Volume (30 Days) | 121.4K | ★ 2.9M |
| Earning Date | 03-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.86 | $0.51 |
| 52 Week High | $4.08 | $1.51 |
Technical Indicators
Market Signals| Indicator | INVE | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 45.76 |
| Support Level | $3.23 | $0.61 |
| Resistance Level | $3.73 | $1.17 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 48.98 | 1.04 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.